A Study to Evaluate Efficacy and Safety of Casirivimab+Imdevimab (Monoclonal Antibodies) for Prevention of COVID-19 in Immunocompromised Adolescents and Adults

NCT05074433 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

66

Enrollment

INDUSTRY

Sponsor class

Stopped Emerging SARS-CoV2 variants impacting susceptibility to study drug

Conditions

Immunocompromised

Interventions

DRUG: casirivimab+imdevimab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals